论文部分内容阅读
近年来发现,神经元特异性烯醇化酶(Neuron—specific enolase,NSE)及S—100b蛋白(S—100b)作为神经系统特异性的蛋白质不但在中枢神经系统(CNS)疾病时增加,在周围神经系统(PNS)疾病时也增加,而且这些蛋白质对CNS疾病有较好的预后价值。作者测定了格林—巴利综合征(GBS)患者脑脊液(CSF)中NSE和S—100b的血浓度,并就其作为预后指示因子进行了评价。24例GBS患者,其中男15例,女9例,年龄16～64岁(平均33.0±14.8岁),均符合诊断标准。四肢肌软弱的程度从轻瘫到完全麻痹。CSF蛋白水平从21至500mg/dl。21例进行了电生理检查,16例示传导速度异常,如传导示速度减慢,终末潜伏期短暂
In recent years, it has been found that neuron-specific enolase (NSE) and S-100b protein (S-100b), as nervous system-specific proteins, not only increase in the central nervous system (CNS) disease, Nervous system (PNS) diseases also increase, and these proteins have a better prognosis of CNS disease. The authors measured the blood levels of NSE and S-100b in cerebrospinal fluid (CSF) from patients with Guillain-Barré Syndrome (GBS) and evaluated their prognostic factors. 24 cases of GBS patients, including 15 males and 9 females, aged 16 to 64 years (mean, 33.0 ± 14.8 years), all in line with the diagnostic criteria. The degree of limb muscle weakness from paralysis to complete paralysis. CSF protein levels from 21 to 500 mg / dl. 21 cases of electrophysiological examination, 16 cases showed abnormal conduction velocity, such as conduction slowed down, the terminal latency is short